The medications used during the study include several types of antiemetic drugs, which are substances used to prevent or reduce vomiting and nausea. These medications include ondansetron, aprepitant, palonosetron, granisetron, and dexamethasone. Some of these medicines are taken by mouth, while others may be given through an intravenous line, which is a small tube inserted into a vein to deliver medicine directly into the bloodstream, or via subcutaneous injection, which means the medicine is injected just under the skin.

During the course of the study, participants will be assigned to different groups to receive either the new medication or a placebo alongside their current anti-nausea treatments. The different groups will be monitored to see how many people experience a complete response, meaning they have no vomiting and do not need to take extra rescue medicine to manage their symptoms.

Participants in this study will be adults who are scheduled to have either weight loss surgery or gallbladder removal surgery performed using keyhole techniques under general anesthesia. Before the surgery, participants will be asked about their overall health and wellbeing. During the operation, they will receive either the study medications or the comparison medication through a vein. After the surgery, participants will be asked to complete questionnaires about how they are feeling, including questions about nausea, vomiting, pain, and their overall recovery. These questions will be asked on the day of surgery and for the following three days while they are in hospital and at home.

The study will also track how much pain medication and anti-sickness medication participants need to use, how long they stay in the recovery area and in hospital, and whether they experience any side effects from the medications such as reactions at the injection site, headache, vision changes, constipation, diarrhea, or tiredness. Any complications that occur up to thirty days after surgery will be recorded. Some participants will also be invited to take part in interviews between one and three months after their surgery to talk about their experience of recovering from the operation.

The purpose of the study is to see how well IV NEPA works in preventing nausea and vomiting in children receiving chemotherapy. The study will be conducted in two parts. In the first part, children will receive a single dose of IV NEPA and will be compared to those receiving fosaprepitant and ondansetron. In the second part, children will receive repeated doses of IV NEPA and will be compared to those receiving a combination of aprepitant and ondansetron. The study will monitor the safety and effectiveness of these treatments over time.

Participants in the study will receive their assigned treatment and will be closely monitored by healthcare professionals. The study aims to provide valuable information on the best ways to prevent nausea and vomiting in children undergoing chemotherapy, helping to improve their comfort and quality of life during treatment. The study is expected to continue until the end of 2027.

In addition to amisulpride, the study will also involve other medications such as dexamethasone phosphate and ondansetron, which are commonly used to manage nausea and vomiting. These medications will be compared to see how well they work in preventing these symptoms. Some participants may receive a placebo, which is a substance with no active medication, to help researchers understand the effectiveness of the treatments being tested.

The study will follow participants for a short period after their surgery to monitor for any signs of nausea or vomiting and to see if they need any additional medication to manage these symptoms. The goal is to find the best way to prevent post-operative nausea and vomiting in children, making their recovery from surgery more comfortable. Participants will be closely monitored for any side effects or adverse reactions to the medications used in the study.

Participants in the study will receive either the medication or a placebo during their chemotherapy treatment. The study is designed in a way that each child will receive both the medication and the placebo at different times, allowing researchers to compare the effects directly. The trial will last for a maximum of eight days during each chemotherapy cycle, and the children will act as their own control, meaning they will receive both treatments in different cycles.

The main goal of the study is to see if extending the use of fosaprepitant and aprepitant can prevent nausea and vomiting more effectively in the days following chemotherapy. The study will also look at the safety of using these medications for a longer time and how they affect the children’s experience of nausea and vomiting. This research is important for improving the quality of life for children undergoing chemotherapy by reducing the discomfort caused by nausea and vomiting.

Participants in the study will receive either aprepitant or a placebo, which is a substance with no active medication. The study will observe the effects of aprepitant on patients undergoing different types of bariatric surgery, such as laparoscopic sleeve gastrectomy, Roux-en-Y gastric bypass, or one-anastomosis mini gastric bypass. The trial will monitor the incidence and severity of PONV, as well as the need for additional medication to manage symptoms.

The study will also look at other factors, such as the length of stay in the recovery room and overall hospital stay, as well as patient satisfaction with their postoperative experience. By understanding how aprepitant affects these outcomes, the trial hopes to improve the recovery process for patients undergoing bariatric surgery.

The purpose of this study is to evaluate how well a single oral dose of Akynzeo works in preventing nausea and vomiting in patients who are receiving chemotherapy for the first time. Participants will receive the treatment during their first cycle of chemotherapy, and the study will monitor their response over a period of 120 hours. Some participants may receive a placebo instead of Akynzeo to compare the effectiveness of the treatment. The study will also assess the safety and tolerability of Akynzeo by monitoring any side effects experienced by the participants.

Throughout the study, participants will be closely observed to see if they achieve a complete response, which means no vomiting and no need for additional medication to control nausea. The study will also look at how well the treatment works during different phases of the chemotherapy cycle, such as the acute phase (first 24 hours) and the delayed phase (24 to 120 hours). The overall goal is to determine if Akynzeo can effectively manage nausea and vomiting in patients with endometrial cancer undergoing chemotherapy, with or without the addition of immunotherapy.